ScreenerHero

PHARM Pharming Group N.V.

AMS · NL · Healthcare · Biotechnology · pharming.com
0.8742EUR+0.46%Mkt Cap: 672.55M $P/E: 87.42

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. Th…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.54BUSDP/E 29.3
MRNA
Moderna, Inc.
$81.13BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$74.79BUSDP/E 18.0
ARGX
argenx SE
$57.11BUSDP/E 34.8
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc.
$44.51BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines AG
$41.14BUSDP/E 64.7
RPRX
Royalty Pharma plc
$32.74BUSDP/E 30.1
ALNY
Alnylam Pharmaceuticals, Inc.
$29.42BUSDP/E 37.1
ROIV
Roivant Sciences Ltd.
$25.84BUSD
BNTX
BioNTech SE
$24.53BUSD
GMAB
Genmab A/S
$24.01BUSDP/E 30.3
INCY
Incyte Corporation
$23.13BUSDP/E 14.5
INSM
Insmed Incorporated
$22.67BUSD
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
JAZZ
Jazz Pharmaceuticals plc
$15.32BUSDP/E 16.2
ASND
Ascendis Pharma A/S
$15.01BUSDP/E 17.5
EXEL
Exelixis, Inc.
$14.58BUSDP/E 18.6
SMMT
Summit Therapeutics Inc.
$13.78BUSD

Key Statistics

Company
Market Cap672.55M USD
Enterprise Value620.57M USD
Revenue (TTM)398.35M USD
Gross Profit359.38M USD
Net Income (TTM)3.10M USD
Revenue/Share0.52 EUR
Last Price0.8742 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees407
CountryNL
SectorHealthcare
IndustryBiotechnology
ISINNL0010391025
Valuation
P/E (Trailing)87.42
P/E (Forward)34.99
PEG—
EV/EBITDA17.36
EV/Revenue1.56
P/S1.68
P/B2.65
EPS (TTM)0.01
EPS (Forward)0.02
52W Range
0.83384% of range1.818
52W High1.818 EUR
52W Low0.8338 EUR
Profitability
Gross Margin87.90%
Oper. Margin1.46%
EBITDA Margin8.97%
Profit Margin0.76%
ROE1.03%
ROA0.57%
Growth
Revenue Growth-3.20%
Earnings Growth-62.90%
Cash Flow & Leverage
Operating CF59.47M USD
CapEx (TTM)820.65K USD
FCF Margin10.28%
FCF Yield6.09%
Net Debt-48.90M USD
Net Debt/EBITDA-1.37
Balance Sheet
Debt/Equity0.42
Current Ratio3.01
Quick Ratio2.31
Book Value/Sh0.33 EUR
Cash/Share0.22 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 EUR
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateMar 5, 2013
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)2.249 EUR
Upside (mean)+157.3%
Target Range2.020 EUR – 2.484 EUR
2.020+157.3% to mean2.484
# Analysts3
Ownership
Shares Out.707.78M
Float696.57M
Insiders1.91%
Institutions23.41%
Technical
SMA 500.9614 (-9.1%)
SMA 2001.239 (-29.4%)
Beta0.07
S&P 52W Chg14.58%
Avg Vol (30d)6.82M
Avg Vol (10d)8.28M
Technical Indicators
RSI (14)35.5
MACD-0.0271
MACD Signal-0.0241
MACD Hist.-0.0030
BB Upper0.9753 EUR
BB Middle0.9194 EUR
BB Lower0.8636 EUR
BB Width12.16%
ATR (14)0.0305 EUR
Vol Ratio (20d)0.60x